FeesSafety
Pluang+

Eikon Therapeutics gets FDA nod to start Phase 1/2 trial of EIK1006 for advanced prostate cancer

Market News
17 Nov 2026, 13:00 WIB
GlobeNewsWire
View Source
Bullish
Eikon Therapeutics gets FDA nod to start Phase 1/2 trial of EIK1006 for advanced prostate cancer

Eikon Therapeutics announced FDA clearance to begin a Phase 1/2 clinical trial for EIK1006, a novel androgen receptor antagonist targeting advanced metastatic prostate cancer resistant to current therapies. The study will assess safety, tolerability, and preliminary efficacy in patients with metastatic androgen-pathway-modulation-resistant prostate cancer. Dosing is expected to start in 2027, with initial data anticipated in the second half of the year. This milestone highlights Eikon's progress in addressing a critical unmet need in prostate cancer treatment.

Eikon Therapeutics' novel androgen receptor antagonist EIK1006 is entering a Phase 1/2 study following FDA clearance. For readers following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 18:01 WIB: out of 150 priced US health stocks, 50 rose and 84 fell. Notable movers include Humana Inc (HUM) at USD 447.00 with a typical hold time of 51 days and 100% buy order activity, Cogent Biosciences Inc. (COGT) at USD 28.20 with 100% sell order activity, and CVS Health Corp (CVS) at USD 86.20 with 88% sell order activity and a typical hold time of 80 days.

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
58 minutes ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
58 minutes ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
58 minutes ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
58 minutes ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
58 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App